These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8825117)

  • 1. Recombinant immunotoxins.
    Pastan I; Pai LH; Brinkmann U; FitzGerald D
    Breast Cancer Res Treat; 1996; 38(1):3-9. PubMed ID: 8825117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
    Reiter Y; Wright AF; Tonge DW; Pastan I
    Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First immunotoxin therapy for many common solid tumors enters phase I clinical trial.
    Skolnick AA
    JAMA; 1993 Nov; 270(19):2280. PubMed ID: 8230582
    [No Abstract]   [Full Text] [Related]  

  • 4. Pseudomonas exotoxin: recombinant conjugates as therapeutic agents.
    FitzGerald DJ; Pastan I
    Biochem Soc Trans; 1992 Nov; 20(4):731-4. PubMed ID: 1487051
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant immunotoxins: new therapeutic agents for cancer treatment.
    Pastan IH
    Cancer Detect Prev; 1993; 17(2):289-93. PubMed ID: 8402714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy of cancer with recombinant immunotoxins.
    Pastan I
    Biochim Biophys Acta; 1997 Oct; 1333(2):C1-6. PubMed ID: 9395287
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting Pseudomonas exotoxin to hematologic malignancies.
    Kreitman RJ; Pastan I
    Semin Cancer Biol; 1995 Oct; 6(5):297-306. PubMed ID: 8562907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically engineered proteins for immunoregulation.
    Strom TB; Steele AW; Nichols J
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):18-20. PubMed ID: 7482811
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotoxins and recombinant toxins for cancer treatment.
    Pai LH; Pastan I
    Important Adv Oncol; 1994; ():3-19. PubMed ID: 8206493
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotoxins and recombinant toxins in the treatment of solid carcinomas.
    Theuer CP; Pastan I
    Am J Surg; 1993 Sep; 166(3):284-8. PubMed ID: 8368439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
    Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
    Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
    Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
    Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
    Benhar I; Pastan I
    Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotoxin therapy for cancer.
    Pai LH; Pastan I
    JAMA; 1993 Jan; 269(1):78-81. PubMed ID: 8416411
    [No Abstract]   [Full Text] [Related]  

  • 15. Recombinant single-chain immunotoxins against T and B cell leukemias.
    Kreitman RJ; Pastan I
    Leuk Lymphoma; 1994 Mar; 13(1-2):1-10. PubMed ID: 8025511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
    Kuan CT; Pastan I
    Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.
    Pearson JW; Hedrick E; Fogler WE; Bull RL; Ferris DK; Riggs CW; Wiltrout RH; Sivam G; Morgan AC; Groves E
    Cancer Res; 1990 Oct; 50(19):6379-88. PubMed ID: 2144790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin.
    Batra JK; Jinno Y; Chaudhary VK; Kondo T; Willingham MC; FitzGerald DJ; Pastan I
    Proc Natl Acad Sci U S A; 1989 Nov; 86(21):8545-9. PubMed ID: 2510169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant toxins: new therapeutic agents for cancer.
    Pastan IH; Pai LH; Brinkmann U; Fitzgerald DJ
    Ann N Y Acad Sci; 1995 Jun; 758():345-54. PubMed ID: 7625703
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor.
    Pai-Scherf LH; Villa J; Pearson D; Watson T; Liu E; Willingham MC; Pastan I
    Clin Cancer Res; 1999 Sep; 5(9):2311-5. PubMed ID: 10499598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.